Peptide inhibitors of LFA-1/1Cam-1 interaction

Abstract

Cyclic peptides inhibit LFA-1 interaction with ICAM-1 and are useful in treatment of hematopoietic neoplasms and in adjunct therapy in prevention of retinoic acid syndrome and diseases involving emigration of leukocytes into organ tissue.

1 . A composition comprising a cyclic peptide inhibitor of LFA-1/ICAM-1 interaction, wherein said cyclic peptide inhibitor consists of 7-10 amino acids and comprises an amino acid selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54 and SEQ ID NO: 55.  
     
     
         2 . A therapeutic package for dispensing to, or for use in dispensing to, a mammal being treated for a hematopoietic neoplastic disease, myocardial infarction, radiation injury, asthma, rheumatoid arthritis, or lymphoma metastasis, wherein said package contains in a unit dose, an amount of a cyclic peptide of 7-10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54 and SEQ ID NO: 55.  
     
     
         3 . The package of  claim 2 , wherein said package is formulated for intravenous administration.  
     
     
         4 . The package of  claim 2 , wherein said package includes said unit dose in a dry powder form.  
     
     
         5 . The package of  claim 2 , wherein said unit dose will deliver a dose from about 10 μg/Kg to about 500 μg/Kg.  
     
     
         6 . The package of  claim 2 , wherein said unit dose will deliver a dose from about 50 μg/Kg to about 250 μg/Kg.